Is the Novacyt share price too high? Here’s what you need to know

The Novacyt share price is soaring after a strong H1 earnings announcement. But does that mean you should be buying?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Novacyt (LSE:NCYT) have been one of the few companies that has actually benefitted during 2020. Coronavirus has provided them with lucrative contracts for providing vital testing kits to the UK government. It’s no wonder that Novacyt shares have risen from 12p in 2019 to over 380p. At one point, the shares hit nearly 500p! And the Novacyt share price is moving up again after releasing a positive trading update this morning.

The results are in

The company has just released its H1 (first two quarters) results, announcing a pre-tax profit of €40.2m in the six months to 30 June, compared with a loss of €2m a year ago. Revenues were also up 900%. Not bad at all! EBITDA also rose – from €0.2m (2019 H1) to just under €50m. Directors believe demand will grow until “at least the first half of 2021” under the tense conditions presented by Covid-19.

The massive demand for PCR testing kits has of course been the main driver for these results and the rapid advancing of the Novacyt share price. And the company is looking to build upon its success. A new avenue is currently being explored in the launch of a diagnostic test designed to tell the difference between Covid-19 and the flu. This is well-timed, coinciding with the approaching winter flu season. So, the company is looking to the future. But what about the shares?

Is the Novacyt share price too high?

Full-year revenues are expected to exceed €150m and EBITDA to exceed €100m. For a company with a market cap of £280m, that’s a pretty strong performance if the guidance does play out as expected. But we must remember that 2020 has been an exceptional year and a very fortunate one for Novacyt. In 2019, the company recorded a net loss of £6.5m. In fact, 2020 will be the first year that will show any profits. If the Covid-19 threat dwindles (and that’s a big if), will Novacyt be able to sustain this year’s profitability?

Investors are always looking to the future. Part of the current price of a stock is always a judgement of the company’s future performance. The Novacyt share price is no different. The only way the stock can keep rising is by finding new avenues for profitability – especially in a post-Covid age. One hope is that the global contacts and networks that will be created during the pandemic will provide access to wider markets for other products in the future. The firm has repaid all its outstanding debts as well investing heavily in its inventory. Despite this, it was still left with €19.7m in cash flow as of 30 June.

It’s certainly possible that Novacyt could grow over the next few years into a profitable business that would justify the massive recent share price growth. At the same time, it’s also possible that 2020–21 was a brief period of fortune and the days of profit will disappear as quickly as they arrived. At this stage, in my opinion, you have probably missed the bargain that early 2020 provided.  

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Toby Aston has no position in any of the share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »